Doctors Are Now Prescribing Video Games and AI Apps to Treat Mental Health

Screen time has long been cast as the primary villain in the modern pediatric mental health crisis, blamed for everything from shortened attention spans to rising anxiety. But a growing coalition of physicians and researchers is attempting to flip that paradigm entirely. Rather than simply advising parents to confiscate devices, pediatricians are increasingly looking to harness the screen as a delivery mechanism for targeted psychiatric treatment. This shift represents a fundamental rethinking of digital engagement, moving away from the idea that all screen time is inherently toxic and toward a model where clinically validated software can be prescribed as medicine to actively repair neural pathways.[1]

This transition is being driven by the rapid maturation of Digital Therapeutics, commonly referred to as DTx. It is crucial to distinguish this emerging class of treatments from the thousands of consumer wellness applications—like Calm or Headspace—that currently flood app stores. Wellness apps are direct-to-consumer products designed for general relaxation and lifestyle support, lacking formal clinical validation. In contrast, digital therapeutics are classified by federal regulators as Software as a Medical Device. They are engineered to directly treat, manage, or prevent specific medical disorders, utilizing code as the active therapeutic ingredient rather than a chemical compound.[4][6]

To earn this rigorous medical designation, software developers cannot rely on user reviews or internal engagement metrics. They must subject their applications to the same gold-standard scrutiny required of traditional pharmaceuticals: double-blind, randomized controlled trials. Only after demonstrating statistically significant safety and efficacy data can these products receive clearance from federal regulators. Once cleared, they are locked behind a pharmacy wall, requiring a formal prescription from a licensed healthcare provider before a patient can download and activate the software on their personal device.[4][6]

The evidence base supporting these digital interventions has expanded significantly over the past few years. As of 2026, regulators have authorized more than a dozen distinct digital mental health products. This portfolio of prescription software now targets a wide spectrum of psychiatric and behavioral conditions, including chronic insomnia, substance use disorder, opioid use disorder, generalized anxiety, and postpartum depression. However, the most intense clinical interest—and the most rigorous debate over efficacy—has centered on treatments developed for attention-deficit/hyperactivity disorder and major depressive disorder.[6]

The foundational claim of the pediatric digital therapeutic movement is that highly engineered video games can objectively improve attention function in children with ADHD. The pioneer in this specific space is EndeavorRx, developed by Akili Interactive. In 2020, it made medical history by becoming the first video game to ever be cleared by federal regulators as a prescription medical treatment, specifically authorized for children between the ages of eight and twelve who have demonstrated primarily inattentive or combined-type ADHD.[2]

EndeavorRx is explicitly not designed for leisure or entertainment, despite its colorful interface. The software runs on a proprietary algorithm known as the Selective Stimulus Management Engine. During a standard treatment session, a child is tasked with steering a character along a continuously moving course. As they navigate, the engine bombards them with specific visual and auditory stimuli, forcing the patient to constantly multitask, prioritize targets, and actively ignore engineered distractions. The algorithm continuously adapts in real-time, increasing the cognitive difficulty the moment the child's attention improves.[2][5]

The clinical data supporting this digital intervention is substantial. Across five clinical studies involving more than 600 children, researchers measured the game's impact using the Test of Variables of Attention, a widely accepted objective computer-based assessment. The pivotal trial revealed a 36 percent improvement in at least one objective measure of attention among the children who used the software. Furthermore, clinical responder rates ranged between 48 and 50 percent after just one month of daily 25-minute gameplay sessions, suggesting a significant therapeutic impact for half of the patient population.[2][5]

However, this evidence comes with strict and transparent caveats regarding its real-world application. Regulatory authorization documents explicitly note that while the video game successfully improves computer-assessed attention metrics, it "may not display benefits in typical behavioral symptoms, such as hyperactivity." Because the software does not necessarily translate to a calmer child in a physical classroom setting, it is authorized strictly as an adjunct therapy. It is intended to be used alongside traditional clinician-directed therapy, educational programs, and standard stimulant medications, rather than serving as a standalone cure.[2]

Beyond pediatric ADHD, the digital therapeutic industry has recently expanded its focus to adult psychiatric care, making the claim that smartphone applications can actively reduce the severity of Major Depressive Disorder. In the spring of 2024, regulators cleared Rejoyn, a prescription application developed jointly by Click Therapeutics and Otsuka Pharmaceutical. The software is authorized for adults aged 22 and older who are already taking standard antidepressant medications but are still experiencing partial, lingering depressive symptoms that disrupt their daily lives.[3]

Rejoyn operates on the theory of neuroplasticity, targeting specific working memory deficits that are heavily associated with clinical depression. The core of the six-week digital treatment involves a novel cognitive emotional training exercise. Users are presented with a rapid sequence of faces depicting various complex emotions. They are then required to recall the exact sequence and identify the emotions, a task designed to rebuild neural connections and rework how the patient's brain processes and stores emotional material, supplemented by brief cognitive-behavioral therapy lessons.[3]

The pivotal clinical trial for Rejoyn involved 354 adults diagnosed with current Major Depressive Disorder. At the beginning of the study, participants scored an average of 28 on the Montgomery-Asberg Depression Rating Scale, a clinical benchmark indicating moderate depression. Participants were randomly divided, with half receiving the active Rejoyn application and the other half receiving a placebo application. After six weeks of consistent use, the average depression score among the Rejoyn users dropped significantly from 28 down to 19, indicating a meaningful reduction in symptom severity.[3]

Despite this drop, the strength of the evidence has been heavily debated within the psychiatric community due to the performance of the control group. The patients using the "sham app"—a placebo game that required similar effort but only involved matching shapes instead of emotional faces—also saw their depression scores drop significantly, landing at an average of 21. Because the two-point difference between the active therapeutic app and the digital placebo was not deemed statistically significant on the trial's primary outcome measure, some experts urge caution, questioning how much of the benefit is driven by the specific emotional training versus the general placebo effect of structured daily engagement.[3]

Even with ongoing debates over the exact magnitude of their clinical effect sizes, the safety profile of digital therapeutics remains a massive draw for both patients and prescribing physicians. Traditional psychiatric medications often carry heavy burdens, ranging from severe appetite suppression and sleep disruption in pediatric ADHD stimulants to weight gain and emotional blunting in adult antidepressants. In stark contrast, the most common adverse event reported in the EndeavorRx trials was mild frustration with the game's difficulty, while the Rejoyn trials reported virtually no adverse effects, offering a uniquely low-risk adjunct for struggling patients.[2]

Historically, the primary hurdle preventing the widespread adoption of digital therapeutics has been financial rather than clinical. For years, insurance companies balked at the idea of reimbursing patients for software downloads, leaving these treatments inaccessible to lower-income populations. However, the reimbursement landscape shifted dramatically in 2025 when the Centers for Medicare and Medicaid Services established dedicated billing codes specifically for digital mental health treatments. This regulatory milestone provided a clear pathway for providers to bill for software interventions, signaling a permanent transition toward mainstream insurance coverage.[4]

Looking ahead, the medical community is demanding increasingly rigorous standards for the next generation of therapeutic software. Leading pediatricians and psychiatric researchers are actively pushing the digital health industry to permanently abandon standard tech-industry "engagement metrics"—which merely measure how long an app can hold a user's attention—in favor of designing tools that deliver durable, real-world developmental outcomes. As the technology evolves, the ultimate goal is to create a highly regulated ecosystem where a digital prescription is trusted with the exact same confidence as a chemical one.[1][7]